港股異動 | 騰盛博藥-B漲近9% 股價創逾5個月新高
格隆匯1月30日丨港股生物醫藥股走強,其中騰盛博藥-B漲8.92%,報10.14港元,股價創逾5個月新高,總市值74億港元,成交達1.86億港元。2022年12月30日,國家藥監局發佈消息稱,按照藥品特別審批程序,已經應急附條件批准默沙東公司新冠病毒治療藥物莫諾拉韋膠囊進口註冊。而早在2022年9月,默沙東將莫諾拉韋在中國境內的經銷權和獨家進口權授予國藥集團,而國藥集團是國藥控股的控股股東。據騰盛博藥2022年3月30日宣佈,其控股公司騰盛華創與國藥控股達成戰略合作,雙方將共同攜手推進長效新冠單克隆中和抗體安巴韋單抗/羅米司韋單抗聯合療法的商業化進程。中信建投發研報指,關於2022年四季度業績高增細分板塊,可關注新冠藥產業鏈等。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.